<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00050622</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH062946</org_study_id>
    <secondary_id>R01MH062946</secondary_id>
    <secondary_id>DSIR CT-CT</secondary_id>
    <nct_id>NCT00050622</nct_id>
  </id_info>
  <brief_title>Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>ADHD Treatment: Comparative and Combined Dosage Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida International University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Florida International University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of behavioral treatment, drug
      treatment, and combined treatment for children with Attention Deficit Hyperactivity Disorder
      (ADHD). This study will also examine the interactions between different levels of behavioral
      and drug treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants attend a summer treatment program each Monday-Friday for 9 weeks. They
      participate in group recreational and classroom activities, with 12 children and 5 staff per
      group. Three behavioral conditions (no behavioral modification, low-intensity behavioral
      modification, and high-intensity behavioral modification) are delivered in random order, with
      each condition lasting 3 weeks. Along with the behavioral treatment conditions, children
      receive 1 of 4 medication doses (placebo, 0.15 mg/kg methylphenidate, 0.3 mg/kg
      methylphenidate, or 0.6 mg/kg methylphenidate) in random order, with each dose varied daily
      and repeated 3 or 4 times within each behavioral treatment condition.

      Measures include frequency counts of positive and negative behaviors, academic productivity
      and accuracy in the classroom, and counselor, parent, and teacher ratings of benefits and
      side effects. Parents attend training sessions and implement behavioral programs at home.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Social Behavior-Negative Verbalizations</measure>
    <time_frame>Daily for 45 days</time_frame>
    <description>Sum of daily frequency of Verbal Abuse toward staff members, Teasing toward peers, and Cursing/Swearing as defined by a behavioral point system that doubles as an objective measure of children's behavior. All instances of these behaviors were reported and noted as they occur throughout daily activities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Classroom Behavior</measure>
    <time_frame>Daily for 45 days</time_frame>
    <description>Daily records of percentage of assigned problems completed by children in a 60-minute classroom period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction</measure>
    <time_frame>End of Treatment</time_frame>
    <description>Parent rating of treatment satisfaction with medication, behavioral treatment, and their combination,on a scale of 1 (bad) to 7 (good).</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No Medication, No Behavior Modification (BMOD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Medication Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.15 mg/kg methylphenidate (MPH), No BMOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose Medication Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3 mg/kg MPH, No BMOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher Dose Medication Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.6 mg/kg MPH, No BMOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity BMOD Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo, Low Intensity BMOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity BMOD + Low Dose Medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.15 mg/kg MPH, Low Intensity BMOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity BMOD + Medium Dose Medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3 mg/kg MPH, Low Intensity BMOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity BMOD + Higher Dose Medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.6 mg/kg MPH, Low Intensity BMOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity BMOD Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo, High Intensity BMOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity BMOD + Low Dose Medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.15 mg/kg MPH, High Intensity BMOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity BMOD + Medium Dose Medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3 mg/kg MPH, High Intensity BMOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity BMOD + Higher Dose Medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.6 mg/kg MPH, High Intensity BMOD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate 0.15 mg/kg</intervention_name>
    <description>0.15 m/kg/dose immediate-release methylphenidate</description>
    <arm_group_label>Low Dose Medication Only</arm_group_label>
    <arm_group_label>Low Intensity BMOD + Low Dose Medication</arm_group_label>
    <arm_group_label>High Intensity BMOD + Low Dose Medication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low-Intensity BMOD</intervention_name>
    <description>Lower-intensity behavioral treatment package.</description>
    <arm_group_label>Low Intensity BMOD Only</arm_group_label>
    <arm_group_label>Low Intensity BMOD + Low Dose Medication</arm_group_label>
    <arm_group_label>Low Intensity BMOD + Medium Dose Medication</arm_group_label>
    <arm_group_label>Low Intensity BMOD + Higher Dose Medication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate 0.3 mg/kg</intervention_name>
    <description>0.3 mg/kg/dose immediate-release methylphenidate</description>
    <arm_group_label>Medium Dose Medication Only</arm_group_label>
    <arm_group_label>Low Intensity BMOD + Medium Dose Medication</arm_group_label>
    <arm_group_label>High Intensity BMOD + Medium Dose Medication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>No Treatment</arm_group_label>
    <arm_group_label>Low Intensity BMOD Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate 0.6 mg/kg</intervention_name>
    <description>0.3 mg/kg/dose immediate-release methylphenidate</description>
    <arm_group_label>Higher Dose Medication Only</arm_group_label>
    <arm_group_label>Low Intensity BMOD + Higher Dose Medication</arm_group_label>
    <arm_group_label>High Intensity BMOD + Higher Dose Medication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>High Intensity BMOD</intervention_name>
    <description>Comprehensive high-intensity Summer Treatment Program (STP)</description>
    <arm_group_label>High Intensity BMOD Only</arm_group_label>
    <arm_group_label>High Intensity BMOD + Low Dose Medication</arm_group_label>
    <arm_group_label>High Intensity BMOD + Medium Dose Medication</arm_group_label>
    <arm_group_label>High Intensity BMOD + Higher Dose Medication</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Attention Deficit Hyperactivity Disorder

          -  IQ &gt;= 80

        Exclusion Criteria:

          -  History of seizures or other neurological problems

          -  Medical history that would involve considerable risk in taking stimulant medication

          -  History or concurrent diagnosis of any of the following disorders: pervasive
             developmental disorder, schizophrenia or other psychotic disorders, sexual disorder,
             organic mental disorder, or eating disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William E Pelham, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, Florida International University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida International University Center for Children and Families</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Children and Families, University at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ccf.fiu.edu</url>
    <description>Center for Children and Families Home Page</description>
  </link>
  <reference>
    <citation>Fabiano, G.A., Pelham, W.E., Gnagy, E.M., Wymbs, B.T., Chacko, A., Coles, E.K., Walker, K.S., Arnold, F., Burrows-MacLean, L., Massetti, G.M., &amp; Hoffman, M.T. (2007). The single and combined effects of multiple intensities of behavior modification and multiple intensities of methylphenidate in a classroom setting. School Psychology Review, 36(2), 195-216.</citation>
  </reference>
  <reference>
    <citation>Pelham WE, Burrows-MacLean L, Gnagy EM, Fabiano GA, Coles EK, Wymbs BT, Chacko A, Walker KS, Wymbs F, Garefino A, Hoffman MT, Waxmonsky JG, Waschbusch DA. A dose-ranging study of behavioral and pharmacological treatment in social settings for children with ADHD. J Abnorm Child Psychol. 2014 Aug;42(6):1019-31. doi: 10.1007/s10802-013-9843-8.</citation>
    <PMID>24429997</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2002</study_first_submitted>
  <study_first_submitted_qc>December 16, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2002</study_first_posted>
  <results_first_submitted>May 31, 2016</results_first_submitted>
  <results_first_submitted_qc>August 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2016</results_first_posted>
  <last_update_submitted>August 8, 2016</last_update_submitted>
  <last_update_submitted_qc>August 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Within-Subject Treatment</title>
          <description>All subjects received a within-subjects crossover of 3 levels of behavior modification, randomized in 3-week units, and 4 levels of medication, randomized on a daily basis. Thus each participant experienced all 12 combinations of No, Low, and High Intensity BMOD crossed with Placebo, 0.15 mg/kg MPH, 0.3 mg/kg MPH, and 0.6 mg/kg MPH conditions, with specific conditions changing daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Within-Subject Treatment</title>
          <description>All subjects completed a within-subjects crossover of 3 levels of behavior modification and 4 levels of medication.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.15" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Social Behavior-Negative Verbalizations</title>
        <description>Sum of daily frequency of Verbal Abuse toward staff members, Teasing toward peers, and Cursing/Swearing as defined by a behavioral point system that doubles as an objective measure of children's behavior. All instances of these behaviors were reported and noted as they occur throughout daily activities.</description>
        <time_frame>Daily for 45 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>No Medication, No BMOD
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Medication Only</title>
            <description>0.15 mg/kg MPH, No BMOD
Methylphenidate 0.15 mg/kg: 0.15 m/kg/dose immediate-release methylphenidate</description>
          </group>
          <group group_id="O3">
            <title>Medium Dose Medication Only</title>
            <description>0.3 mg/kg MPH, No BMOD
Methylphenidate 0.3 mg/kg: 0.3 mg/kg/dose immediate-release methylphenidate</description>
          </group>
          <group group_id="O4">
            <title>Higher Dose Medication Only</title>
            <description>0.6 mg/kg MPH, No BMOD
Methylphenidate 0.6 mg/kg: 0.3 mg/kg/dose immediate-release methylphenidate</description>
          </group>
          <group group_id="O5">
            <title>Low Intensity BMOD Only</title>
            <description>Placebo, Low Intensity BMOD
Low-Intensity BMOD: Lower-intensity behavioral treatment package.
Placebo</description>
          </group>
          <group group_id="O6">
            <title>Low Intensity BMOD + Low Dose Medication</title>
            <description>0.15 mg/kg MPH, Low Intensity BMOD
Methylphenidate 0.15 mg/kg: 0.15 m/kg/dose immediate-release methylphenidate
Low-Intensity BMOD: Lower-intensity behavioral treatment package.</description>
          </group>
          <group group_id="O7">
            <title>Low Intensity BMOD + Medium Dose Medication</title>
            <description>0.3 mg/kg MPH, Low Intensity BMOD
Low-Intensity BMOD: Lower-intensity behavioral treatment package.
Methylphenidate 0.3 mg/kg: 0.3 mg/kg/dose immediate-release methylphenidate</description>
          </group>
          <group group_id="O8">
            <title>Low Intensity BMOD + Higher Dose Medication</title>
            <description>0.6 mg/kg MPH, Low Intensity BMOD
Low-Intensity BMOD: Lower-intensity behavioral treatment package.
Methylphenidate 0.6 mg/kg: 0.3 mg/kg/dose immediate-release methylphenidate</description>
          </group>
          <group group_id="O9">
            <title>High Intensity BMOD Only</title>
            <description>Placebo, High Intensity BMOD
High Intensity BMOD: Comprehensive high-intensity STP</description>
          </group>
          <group group_id="O10">
            <title>High Intensity BMOD + Low Dose Medication</title>
            <description>0.15 mg/kg MPH, High Intensity BMOD
Methylphenidate 0.15 mg/kg: 0.15 m/kg/dose immediate-release methylphenidate
High Intensity BMOD: Comprehensive high-intensity STP</description>
          </group>
          <group group_id="O11">
            <title>High Intensity BMOD + Medium Dose Medication</title>
            <description>0.3 mg/kg MPH, High Intensity BMOD
Methylphenidate 0.3 mg/kg: 0.3 mg/kg/dose immediate-release methylphenidate
High Intensity BMOD: Comprehensive high-intensity STP</description>
          </group>
          <group group_id="O12">
            <title>High Intensity BMOD + Higher Dose Medication</title>
            <description>0.6 mg/kg MPH, High Intensity BMOD
Methylphenidate 0.6 mg/kg: 0.3 mg/kg/dose immediate-release methylphenidate
High Intensity BMOD: Comprehensive high-intensity STP</description>
          </group>
        </group_list>
        <measure>
          <title>Social Behavior-Negative Verbalizations</title>
          <description>Sum of daily frequency of Verbal Abuse toward staff members, Teasing toward peers, and Cursing/Swearing as defined by a behavioral point system that doubles as an objective measure of children's behavior. All instances of these behaviors were reported and noted as they occur throughout daily activities.</description>
          <units>Number of Observed Behaviors</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="153"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
                <count group_id="O7" value="153"/>
                <count group_id="O8" value="153"/>
                <count group_id="O9" value="153"/>
                <count group_id="O10" value="153"/>
                <count group_id="O11" value="153"/>
                <count group_id="O12" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.32" spread="127.11"/>
                    <measurement group_id="O2" value="45.41" spread="85.23"/>
                    <measurement group_id="O3" value="28.41" spread="59.11"/>
                    <measurement group_id="O4" value="15.08" spread="29.61"/>
                    <measurement group_id="O5" value="27.06" spread="45.77"/>
                    <measurement group_id="O6" value="13.70" spread="27.99"/>
                    <measurement group_id="O7" value="9.27" spread="20.05"/>
                    <measurement group_id="O8" value="4.28" spread="9.91"/>
                    <measurement group_id="O9" value="20.23" spread="41.13"/>
                    <measurement group_id="O10" value="7.61" spread="19.21"/>
                    <measurement group_id="O11" value="4.08" spread="8.59"/>
                    <measurement group_id="O12" value="2.49" spread="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Classroom Behavior</title>
        <description>Daily records of percentage of assigned problems completed by children in a 60-minute classroom period.</description>
        <time_frame>Daily for 45 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>No Medication, No BMOD
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Medication Only</title>
            <description>0.15 mg/kg MPH, No BMOD
Methylphenidate 0.15 mg/kg: 0.15 m/kg/dose immediate-release methylphenidate</description>
          </group>
          <group group_id="O3">
            <title>Medium Dose Medication Only</title>
            <description>0.3 mg/kg MPH, No BMOD
Methylphenidate 0.3 mg/kg: 0.3 mg/kg/dose immediate-release methylphenidate</description>
          </group>
          <group group_id="O4">
            <title>Higher Dose Medication Only</title>
            <description>0.6 mg/kg MPH, No BMOD
Methylphenidate 0.6 mg/kg: 0.3 mg/kg/dose immediate-release methylphenidate</description>
          </group>
          <group group_id="O5">
            <title>Low Intensity BMOD Only</title>
            <description>Placebo, Low Intensity BMOD
Low-Intensity BMOD: Lower-intensity behavioral treatment package.
Placebo</description>
          </group>
          <group group_id="O6">
            <title>Low Intensity BMOD + Low Dose Medication</title>
            <description>0.15 mg/kg MPH, Low Intensity BMOD
Methylphenidate 0.15 mg/kg: 0.15 m/kg/dose immediate-release methylphenidate
Low-Intensity BMOD: Lower-intensity behavioral treatment package.</description>
          </group>
          <group group_id="O7">
            <title>Low Intensity BMOD + Medium Dose Medication</title>
            <description>0.3 mg/kg MPH, Low Intensity BMOD
Low-Intensity BMOD: Lower-intensity behavioral treatment package.
Methylphenidate 0.3 mg/kg: 0.3 mg/kg/dose immediate-release methylphenidate</description>
          </group>
          <group group_id="O8">
            <title>Low Intensity BMOD + Higher Dose Medication</title>
            <description>0.6 mg/kg MPH, Low Intensity BMOD
Low-Intensity BMOD: Lower-intensity behavioral treatment package.
Methylphenidate 0.6 mg/kg: 0.3 mg/kg/dose immediate-release methylphenidate</description>
          </group>
          <group group_id="O9">
            <title>High Intensity BMOD Only</title>
            <description>Placebo, High Intensity BMOD
High Intensity BMOD: Comprehensive high-intensity STP</description>
          </group>
          <group group_id="O10">
            <title>High Intensity BMOD + Low Dose Medication</title>
            <description>0.15 mg/kg MPH, High Intensity BMOD
Methylphenidate 0.15 mg/kg: 0.15 m/kg/dose immediate-release methylphenidate
High Intensity BMOD: Comprehensive high-intensity STP</description>
          </group>
          <group group_id="O11">
            <title>High Intensity BMOD + Medium Dose Medication</title>
            <description>0.3 mg/kg MPH, High Intensity BMOD
Methylphenidate 0.3 mg/kg: 0.3 mg/kg/dose immediate-release methylphenidate
High Intensity BMOD: Comprehensive high-intensity STP</description>
          </group>
          <group group_id="O12">
            <title>High Intensity BMOD + Higher Dose Medication</title>
            <description>0.6 mg/kg MPH, High Intensity BMOD
Methylphenidate 0.6 mg/kg: 0.3 mg/kg/dose immediate-release methylphenidate
High Intensity BMOD: Comprehensive high-intensity STP</description>
          </group>
        </group_list>
        <measure>
          <title>Classroom Behavior</title>
          <description>Daily records of percentage of assigned problems completed by children in a 60-minute classroom period.</description>
          <units>Percentage of Work Completed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="153"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="153"/>
                <count group_id="O7" value="153"/>
                <count group_id="O8" value="153"/>
                <count group_id="O9" value="153"/>
                <count group_id="O10" value="153"/>
                <count group_id="O11" value="153"/>
                <count group_id="O12" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" spread="23"/>
                    <measurement group_id="O2" value="53" spread="26"/>
                    <measurement group_id="O3" value="57" spread="24"/>
                    <measurement group_id="O4" value="61" spread="23"/>
                    <measurement group_id="O5" value="53" spread="21"/>
                    <measurement group_id="O6" value="67" spread="18"/>
                    <measurement group_id="O7" value="72" spread="19"/>
                    <measurement group_id="O8" value="75" spread="38"/>
                    <measurement group_id="O9" value="58" spread="22"/>
                    <measurement group_id="O10" value="72" spread="17"/>
                    <measurement group_id="O11" value="75" spread="14"/>
                    <measurement group_id="O12" value="76" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction</title>
        <description>Parent rating of treatment satisfaction with medication, behavioral treatment, and their combination,on a scale of 1 (bad) to 7 (good).</description>
        <time_frame>End of Treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>No BMOD, No medication</description>
          </group>
          <group group_id="O2">
            <title>Low Intensity BMOD Only</title>
          </group>
          <group group_id="O3">
            <title>High Intensity BMOD ONly</title>
          </group>
          <group group_id="O4">
            <title>Medication Only</title>
            <description>No BMOD + Medication (any dose)</description>
          </group>
          <group group_id="O5">
            <title>Low Intensity BMOD + Med</title>
            <description>Low intensity behavior modification + medication (any dose)</description>
          </group>
          <group group_id="O6">
            <title>High Intensity BMOD + Medication</title>
            <description>High Intensity BMOD + Medication (any dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction</title>
          <description>Parent rating of treatment satisfaction with medication, behavioral treatment, and their combination,on a scale of 1 (bad) to 7 (good).</description>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="143"/>
                <count group_id="O5" value="143"/>
                <count group_id="O6" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.2"/>
                    <measurement group_id="O2" value="2.7" spread="1.4"/>
                    <measurement group_id="O3" value="3.8" spread="1.6"/>
                    <measurement group_id="O4" value="3.5" spread="1.3"/>
                    <measurement group_id="O5" value="4.6" spread="1.3"/>
                    <measurement group_id="O6" value="5.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Daily for 45 days</time_frame>
      <desc>Parents completed the Pittsburgh Side Effects Rating Scale daily. Side effects were rated as None, Mild, Moderate, or Severe for common side effects of stimulant medication. Because the Side Effects Rating Scale applies only to medication side effects, treatment arms are collapsed across the three behavioral conditions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Medication</title>
          <description>0.15 mg/kg MPH, No BMOD</description>
        </group>
        <group group_id="E3">
          <title>Medium Dose Medication</title>
          <description>0.3 mg/kg MPH, No BMOD</description>
        </group>
        <group group_id="E4">
          <title>Higher Dose Medication</title>
          <description>0.6 mg/kg MPH, No BMOD</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomachache</sub_title>
                <description>Parent Rating of Moderate or Severe on Pittsburgh Side Effect Rating Scale for Stomach ache.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tics</sub_title>
                <description>Parent Rating of Moderate or Severe verbal or motor tics on the Pittsburgh Side Effects Rating Scale.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Picking at skin, nail biting</sub_title>
                <description>Parent rating of Moderate or Severe on Pittsburgh Side Effects Rating Scale for picking at skin, nail biting, etc.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Buccal-Lingual Movements</sub_title>
                <description>Parent rating of Moderate or Severe on Pittsburgh Side Effects Rating Scale for buccal-lingual movements</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Worried/Anxious</sub_title>
                <description>Parent rating of Moderate or Severe on Pittsburgh Side Effect Rating Scale for worry or anxiety</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dull, tired, listless</sub_title>
                <description>Parent Rating of Moderate or Severe on Pittsburgh Side Effect Rating Scale for being dull, tired or listless.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Parent Report of Moderate or Severe on Pittsburgh Side Effect Rating Scale for Headache.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Parent Rating of Moderate or Severe on Pittsburgh Side Effects Rating Scale for Crabbiness/Irritability</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Tearful, sad,depressed</sub_title>
                <description>Parent Rating of Moderate or Severe on Pittsburgh Side Effects Rating Scale for tearfulness, sadness, or depression.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Trouble Sleeping</sub_title>
                <description>Parent Rating of Moderate or Severe on Pittsburgh Side Effects Rating Scale for trouble sleeping.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Appetite Loss</sub_title>
                <description>Parent Rating of Moderate or Severe on Pittsburgh side Effects Rating Scale for appetite loss.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucinations</sub_title>
                <description>Parent rating of Moderate or Severe on Pittsburgh Side Effects Rating Scale for hallucinations.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social Withdrawal</sub_title>
                <description>Parent Rating of Moderate or Severe on Pittsburgh Side Effects Rating Scale for social withdrawal</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Highly structured environment and direct observational measures were used. Additional study in natural school and home settings will be necessary.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William E. Pelham, Jr.</name_or_title>
      <organization>Florida International University</organization>
      <phone>305-348-3002</phone>
      <email>wpelham@fiu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

